会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • KIT FOR PREPARATION OF ANTIGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES
    • 用于制备抗原特异性细胞淋巴球蛋白的工具包
    • US20110318828A1
    • 2011-12-29
    • US12998550
    • 2009-10-29
    • Susumu SuzukiSeiji KojimaTomoki Naoe
    • Susumu SuzukiSeiji KojimaTomoki Naoe
    • C12N5/0783C12M3/00
    • C12N5/0638A61K2039/5158A61K2039/57C12M23/14C12M33/04C12N5/0636C12N2501/23
    • The invention is intended to further improve the operability, economic efficiency and safety in the preparation of antigen-specific CTLs. The invention provides a preparation kit used for a method for preparing antigen-specific cytotoxic T lymphocytes, the method comprising: a first step for inducing antigen-specific cytotoxic T lymphocytes, wherein the components of the first step include a culture medium contained in an injection vessel, a hermetically sealed culture vessel, and the like; a second step for preparing an activated T cell for antigen presentation, wherein the components of the second step include a culture medium contained in an injection vessel, a hermetically sealed culture vessel, and the like, and a third step for proliferating antigen-specific cytotoxic T lymphocytes, wherein the components of the third step include a culture medium contained in an injection vessel, a hermetically sealed separation vessel, a hermetically sealed culture vessel, and the like.
    • 本发明旨在进一步提高抗原特异性CTL的制备的可操作性,经济效率和安全性。 本发明提供了一种用于制备抗原特异性细胞毒性T淋巴细胞的方法的制备试剂盒,该方法包括:诱导抗原特异性细胞毒性T淋巴细胞的第一步骤,其中第一步的成分包括注射剂中所含的培养基 容器,气密密封培养容器等; 用于制备用于抗原呈递的活化T细胞的第二步骤,其中第二步的组分包括包含在注射容器中的培养基,密封的培养容器等,以及用于增殖抗原特异性细胞毒性的第三步骤 T淋巴细胞,其中第三步的组分包括包含在注射容器中的培养基,气密密封的分离容器,气密密封的培养容器等。
    • 7. 发明申请
    • Indazole derivatives
    • 吲唑衍生物
    • US20070117856A1
    • 2007-05-24
    • US10548475
    • 2004-07-30
    • Yoshihisa OhtaFumihiko KanaiShinji NaraYutaka KandaHiroshi UmeharaYukimasa ShiotsuTomoki NaoeHitoshi KiyoiKeiko KawashimaHiromi AndoMotoki Miyama
    • Yoshihisa OhtaFumihiko KanaiShinji NaraYutaka KandaHiroshi UmeharaYukimasa ShiotsuTomoki NaoeHitoshi KiyoiKeiko KawashimaHiromi AndoMotoki Miyama
    • A61K31/416C07D231/56
    • C07D231/56
    • The present invention provides a compound represented by Formula (I): [wherein R1 represents CONR1aR1b (wherein R1a and R1b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R1a and R1b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, R2 represents a hydrogen atom, CONR2aR2b (wherein R2a and R2b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R2a and R2b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group), NR2cR2d (wherein R2c and R2d may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroaroyl, substituted or unsubstituted ararkyl, substituted or unsubstituted lower alkylsulfonyl or substituted or unsubstituted lower arylsulfonyl) or the like].
    • 本发明提供由式(I)表示的化合物:[其中R 1表示CONR 1a 1b 1b(其中R 1a) R 1b和R 1b可以相同或不同,各自表示氢原子,取代或未取代的低级烷基,取代或未取代的芳基,取代或未取代的芳烷基或取代或未取代的杂环基, 或R 1a和R 1b与相邻的氮原子一起形成取代或未取代的杂环基)等,R 2 O, >表示氢原子,其中R 2a,R 2b和R 2b可以相同或不同, 各自表示氢原子,取代或未取代的低级烷基,取代或未取代的芳基,取代或未取代的芳烷基或取代或未取代的杂环基,或R 2b和R 2b >与t结合在一起 它与氮原子相邻以形成取代或未取代的杂环基),NR 2c R 2d(其中R 2c和R 2d) 取代或未取代的低级烷酰基,取代或未取代的芳酰基,取代或未取代的杂芳酰基,取代或未取代的芳烷基,取代或未取代的低级烷基磺酰基或 取代或未取代的低级芳基磺酰基等)。
    • 8. 发明授权
    • Indazole derivatives
    • 吲唑衍生物
    • US07919517B2
    • 2011-04-05
    • US12275614
    • 2008-11-21
    • Yoshihisa OhtaFumihiko KanaiShinji NaraYutaka KandaHiroshi UmeharaYukimasa ShiotsuTomoki NaoeHitoshi KiyoiKeiko KawashimaHiromi AndoMotoki Miyama
    • Yoshihisa OhtaFumihiko KanaiShinji NaraYutaka KandaHiroshi UmeharaYukimasa ShiotsuTomoki NaoeHitoshi KiyoiKeiko KawashimaHiromi AndoMotoki Miyama
    • A61K31/416C07D231/56
    • C07D231/56
    • The present invention provides a compound represented by Formula (I): [wherein R1 represents CONR1aR1b (wherein R1a and R1b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R1a and R1b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, R2 represents a hydrogen atom, CONR2aR2b (wherein R2a and R2b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R2a and R2b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group), NR2cR2d (wherein R2c and R2d may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroaroyl, substituted or unsubstituted ararkyl, substituted or unsubstituted lower alkylsulfonyl or substituted or unsubstituted lower arylsulfonyl) or the like].
    • 本发明提供由式(I)表示的化合物:[其中R1表示CONR1aR1b(其中R1a和R1b可以相同或不同,各自表示氢原子,取代或未取代的低级烷基,取代或未取代的芳基,取代或未取代的 芳基或取代或未取代的杂环基,或者R1a和R1b与相邻的氮原子一起形成取代或未取代的杂环基)等,R2表示氢原子,CONR2aR2b(其中R2a和R2b可以是 各自表示氢原子,取代或未取代的低级烷基,取代或未取代的芳基,取代或未取代的芳基或取代或未取代的杂环基,或者R 2a和R 2b与相邻的氮原子一起形成取代基 或未取代的杂环基),NR2cR2d(其中R2c和R2d可以相同或不同 取代或未取代的杂芳酰基,取代或未取代的芳酰基,取代或未取代的低级烷基磺酰基或取代或未取代的低级芳基磺酰基)等,其中R 1表示氢原子,取代或未取代的低级烷基,取代或未取代的低级烷酰基,取代或未取代的芳酰基, 。
    • 10. 发明授权
    • CD20 negatively converted B-cell malignant lymphoma cell line and utilization thereof
    • CD20阴性转化B细胞恶性淋巴瘤细胞系及其利用
    • US08496927B2
    • 2013-07-30
    • US12311281
    • 2007-09-21
    • Tomoki NaoeAkihiro TomitaJunji Hiraga
    • Tomoki NaoeAkihiro TomitaJunji Hiraga
    • A01N63/00A01K67/00C12Q1/00A61K49/00
    • G01N33/5052A01K67/0271A01K2207/12A01K2227/105A01K2267/0331C12N5/0694C12N2503/02G01N33/5011G01N2800/44
    • It is intended to provide a tool, a procedure and so on which are useful in developing a therapeutic strategy efficacious in inhibiting or overcoming the resistance against a CD20-directed molecular-targeted drug. Thus, a CD20-negatively converted B-cell malignant lymphocyte cell line is provided. Also, a model animal indicating the pathological conditions of CD20-negatively converted B-cell malignant lymphocyte is provided. Further, a method of screening a substance, which is efficacious against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B cell malignant lymphocyte, is provided. Furthermore, a drug against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B-cell malignant lymphocyte, which is characterized by being used together with a CD20-directed molecular-targeted drug, is provided. In one embodiment, a DNA methylase inhibitor or a histone deacetylase inhibitor is employed as the active ingredient.
    • 旨在提供可用于开发有效抑制或克服对CD20定向分子靶向药物的抗性的治疗策略的工具,程序等。 因此,提供CD20阴性转化的B细胞恶性淋巴细胞细胞系。 另外,提供了指示CD20-负转换的B细胞恶性淋巴细胞的病理状态的模型动物。 此外,提供了筛选对CD20阳性B细胞恶性淋巴细胞或CD20-负向转化的B细胞恶性淋巴细胞有效的物质的方法。 此外,提供了抗CD20阳性B细胞恶性淋巴细胞或CD20阴性转化的B细胞恶性淋巴细胞的药物,其特征在于与CD20定向的分子靶向药物一起使用。 在一个实施方案中,使用DNA甲基化酶抑制剂或组蛋白脱乙酰酶抑制剂作为活性成分。